University Hospital Essen,
Germany

Prof Herrmann is a board certified nuclear medicine physician with 18 plus years of experience in the field of theranostics. After being introduced to radionuclide therapy in thyroid cancer patients and neuroendocrine tumor patients as part of clinical training, he discovered the novel and quickly growing field of theranostics was his scientific passion. For more than 15 years he has dedicated his work to the translation of novel theranostic concepts into the clinic, attempting to significantly impact survival and quality of life of patients. Translational activities include collaboration within preclinical teams, first in human evaluation of new diagnostic and therapeutic concepts, as well as the evolution of such concepts within later phase 2 and 3 studies, aiming for approval by regulatory bodies such as EMA and FDA. Significant professional achievements include the first in human application of the CXCR4-directed 177Lu-Pentixather, the initiation of the theranostic program at UCLA, the initiation of the joint UCSF/UCLA 68Ga-PSMA-11 study resulting in FDA approval, the initiation of the first prospective 177Lu-PSMA-617 phase 2 study in the United States, as well as more recently the introduction of new preclinical and translational programs at Universitätsmedizin Essen, Germany